Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 39,000 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average price of $6.23 per share, with a total value of $242,970.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $19,119,564.73. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, August 9th, Phillip Md Et Al Frost acquired 18,000 shares of Opko Health stock. The stock was acquired at an average price of $6.35 per share, with a total value of $114,300.00.
  • On Tuesday, August 8th, Phillip Md Et Al Frost acquired 5,000 shares of Opko Health stock. The stock was acquired at an average price of $6.05 per share, with a total value of $30,250.00.
  • On Wednesday, August 2nd, Phillip Md Et Al Frost acquired 25,000 shares of Opko Health stock. The stock was acquired at an average price of $6.15 per share, with a total value of $153,750.00.
  • On Tuesday, August 1st, Phillip Md Et Al Frost acquired 46,600 shares of Opko Health stock. The stock was acquired at an average price of $6.25 per share, with a total value of $291,250.00.
  • On Friday, July 28th, Phillip Md Et Al Frost acquired 35,100 shares of Opko Health stock. The stock was acquired at an average price of $6.30 per share, with a total value of $221,130.00.
  • On Thursday, July 27th, Phillip Md Et Al Frost acquired 23,600 shares of Opko Health stock. The stock was acquired at an average price of $6.34 per share, with a total value of $149,624.00.
  • On Wednesday, July 26th, Phillip Md Et Al Frost acquired 36,200 shares of Opko Health stock. The stock was acquired at an average price of $6.39 per share, with a total value of $231,318.00.
  • On Tuesday, July 25th, Phillip Md Et Al Frost purchased 39,800 shares of Opko Health stock. The shares were purchased at an average price of $6.41 per share, with a total value of $255,118.00.
  • On Monday, July 24th, Phillip Md Et Al Frost purchased 45,000 shares of Opko Health stock. The shares were purchased at an average price of $6.42 per share, with a total value of $288,900.00.
  • On Thursday, July 20th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The shares were purchased at an average price of $6.46 per share, with a total value of $34,884.00.

Opko Health, Inc. (OPK) traded up 0.65% on Friday, reaching $6.15. The company had a trading volume of 860,285 shares. The stock’s 50-day moving average price is $6.39 and its 200 day moving average price is $7.30. The firm’s market capitalization is $3.44 billion. Opko Health, Inc. has a 52-week low of $5.99 and a 52-week high of $12.15.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The firm had revenue of $314.20 million during the quarter, compared to analysts’ expectations of $322.64 million. During the same period in the prior year, the company earned $0.02 EPS. The firm’s revenue was down 12.0% on a year-over-year basis. On average, equities analysts anticipate that Opko Health, Inc. will post ($0.20) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Daily Political and is the property of of Daily Political. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/11/opko-health-inc-opk-ceo-phillip-md-et-al-frost-purchases-39000-shares.html.

Hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in shares of Opko Health during the fourth quarter worth $105,000. Timber Hill LLC acquired a new stake in shares of Opko Health during the first quarter worth $114,000. World Asset Management Inc boosted its stake in shares of Opko Health by 23.6% in the first quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company’s stock worth $121,000 after buying an additional 2,900 shares during the period. IFC Holdings Incorporated FL boosted its stake in shares of Opko Health by 15.9% in the first quarter. IFC Holdings Incorporated FL now owns 15,339 shares of the biotechnology company’s stock worth $122,000 after buying an additional 2,100 shares during the period. Finally, Financial Architects Inc boosted its stake in shares of Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock worth $102,000 after buying an additional 4,800 shares during the period. 23.05% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently commented on the company. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th. BidaskClub upgraded Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $19.50 price target on shares of Opko Health in a research report on Friday, June 16th. Jefferies Group LLC restated a “hold” rating and set a $6.50 price target (down from $6.80) on shares of Opko Health in a research report on Thursday. Finally, Barrington Research raised their price target on Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Opko Health currently has a consensus rating of “Buy” and a consensus target price of $14.61.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.